RadSep, Inc., a subsidiary of IBC Advanced Technologies, Inc., provides state-of-the-art purification technology and novel chelators for medical radioisotopes (Ac-225, Ra-224, Ra-225, Ra-226, Ra-228, Th-228, Th-232, Pb-212 and more).
We offer proprietary flowsheets and Molecular Recognition Technology™ (MRT™) resins with:
• high selectivity
• up to 99.99% purity and 99.9+% recovery yield
• fast throughput, rapid kinetics
• high chemical and radiolytic stability, resulting in multiple recycles and minimal waste
• simple, single-step processes
• high loading capacities
• small footprints
• benign reagents
As an award-winning manufacturer, we also offer highly selective chelators for various alpha and beta emitting radioisotopes.
Press Releases
-
IBC Launches Full Range of Best-in-Class Molecular Recognition Technology™ (MRT™) Flowsheets for Highly Selective Separations of Key Radionuclides and Preparation of Novel Chelating Agents for Radionuclide Incorporation into Radiopharmaceuticals
June 20, 2023
- Development of multiple anticancer drugs with radioisotopes is in progress
- Lu-177, Y-90, Cu-67, Ra-223, Ac-225, Pb-212 and At-211 have licensed products or are in clinical trials
- IBC's state-of-the-art MRT™ separation and chelation technologies facilitate production of radiopharmaceuticals based on these and other medical radioisotopes
- Radioisotopes are separated at up to 99.99% purity and 99.9+% recovery yield
-
IBC Addresses Critical Supply Shortages of Ac-225 with Commercially Available Molecular Recognition Technology™ (MRT™) for Highly Selective Separation of Ac-225
June 6, 2024
- Strong clinical potential of radioligand therapy is evident from recently published clinical trial results
- Global supply shortage of Ac-225 is impacting supply to clinical trials
- Demand is increasing for high-purity isotopes to conduct and scale up clinical studies and support regulatory approvals in the US and Europe
- IBC's state-of-the-art highly selective separation technology, MRT™, for Ra-226 recovery and Ac-225 separation will help to address these issues
- Ra-226 and Ac-225 are separated at up to 99.99% purity and with 99.9+% recovery yield
-
IBC launches RadSep, Inc.: Best-in-class, highly selective separations using Molecular Recognition Technology™ (MRT™) for production of critical radioisotopes essential to cancer therapies
- Best-in-class, highly selective separations technology for the radiopharmaceuticals industry
- Exhibitor at the European Association of Nuclear Medicine (EANM) Congress in Hamburg, Germany 20-23 October 2024 at Booth S14 (Exhibition Hall 3)
- Over 36 years of experience with first generation flowsheets for highly selective separation of radium (Ra), lead (Pb), thorium (Th), actinium (Ac), bismuth (Bi), copper (Cu) and others
- Highly selective purification of Ra-228 incorporated in Pb-212 flowsheet used by OranoMed to produce AlphaMedix for treatment of neuroendocrine tumors (NETs)
- Second generation flowsheets to drive increased availability and scaleability of critical radioisotope supply, including Pb-212, Ac-225, Ra-226, Th-227, Bi-213 and others
- Highly selective recovery of radium to nanogram per liter concentrations from brines, mining streams and nuclear wastes
- Waste minimization
- Industrial manufacturing capability